Høydosebehandling med autolog stamcellestøtte (HMAS) - utprøvende behandling
- Prosjektnummer
- 911001
- Ansvarlig person
- Roald Ekanger
- Institusjon
- Helse Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Blod og immunforsvar
- Forskningsaktivitet
Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide.
Transfusion 2004 May;44(5):785-9.
PMID: 15104663
Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
Cancer Immunol Immunother 2004 Aug;53(8):740-7. Epub 2004 mai 5
PMID: 15133630
[Survival after high-dose therapy with autologous stem cell support]
Tidsskr Nor Laegeforen 2004 May;124(10):1374-5.
PMID: 15195173
Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Leuk Res 2004 May;28(5):461-8.
PMID: 15068899
No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide.
J Hematother Stem Cell Res 2003 Jun;12(3):351-8.
PMID: 12857376
Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use.
Hematology 2003 Oct;8(5):313-8.
PMID: 14530173
Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics bet
Publisher: Taylor & Francis Health Sciences, part of the Taylor & Francis Group
Better preservation of early and late hematopoietic progenitor cells (LTC-IC, CFU-Mk, -GM, -E, -GEMM) and CD34+ cell viability w
BONE MARROW TRANSPLANTATION, 31: S197-198 1 MAR 2003
Better preservation of early and late hematopoietic progenitor cells (LTC-IC, CFU-Mk, -GM, -E, -GEMM) and CD34+ cell viability w
BONE MARROW TRANSPL 31: S197-S198 Suppl. 1 MAR 2003
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest